UK urged to keep TB controls tight, as "major problem" persists
This article was originally published in Clinica
UK efforts to control TB must be sustained in order to tackle what remains a "major public health problem". So said the Health Protection Agency (HPA), after announcing a marginal annual fall in new cases last year, from 8,495 in 2006, to 8,417 (-0.9%). "The upward trend in recent years is beginning to stabilise, but the figures are still too high," it said, noting that in 2000, new case reports numbered 6,726. The problem is most acute among certain areas and population groups, notably inner cities: London alone, with 39% (3,265) of UK cases, had a prevalence rate of 43.2 per 100,000, compared with a national average of 8.4 per 100,000.
You may also be interested in...
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.